Nonsteroidal antiinflammatory drugs and the risk of myocardial infarction in the general population

Circulation

Volumn 109, Issue 24, 2004, Pages 3000-3006

  García Rodríguez, Luis A ^a   Varas Lorenzo, Cristina ^b   Maguire, Andrew ^b   González Pérez, Antonio ^a  

^a Department of Pharmacoepidemiology   (Spain)

^b PFIZER INC   (United States)

Author keywords

Aspirin; Epidemiology; Myocardial infarction

Indexed keywords

ACETYLSALICYLIC ACID; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DICLOFENAC; IBUPROFEN; INDOMETACIN; KETOPROFEN; MELOXICAM; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CASE CONTROL STUDY; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HEART DEATH; HEART INFARCTION; HEART PROTECTION; HUMAN; INCIDENCE; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PHARMACODYNAMICS; POPULATION RESEARCH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; STATISTICAL ANALYSIS; UNITED KINGDOM;

AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; CARDIOTONIC AGENTS; CASE-CONTROL STUDIES; COHORT STUDIES; COMORBIDITY; CORONARY DISEASE; CYCLOOXYGENASE INHIBITORS; DICLOFENAC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; DRUG UTILIZATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IBUPROFEN; LACTONES; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NAPROXEN; ODDS RATIO; RISK FACTORS; SPAIN; SULFONES;

EID: 3042558200     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000132491.96623.04     Document Type: Article

References (26)

1. Patrono C, Coller B, Dalen JE, et al. Platelet-active drugs: the relationships among dose, effectiveness, and side effects. Chest. 2001; 119(suppl 1):39S-63S.
2. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis: VIGOR Study Group. N Engl J Med. 2000;343:1520-1528.
3. McAdam BF, Catella-Lawson F, Mardini IA, et al. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci USA. 1999;96: 272-277.
4. Rahme E, Pilote L, LeLorier J. Association between naproxen use and protection against acute myocardial infarction. Arch Intern Med. 2002; 162:1111-1115.
5. Ray WA, Stein CM, Hall K, et al. Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study. Lancet. 2002;359:118-123.
6. Schlienger RG, Jick H, Meier CR. Use of nonsteroidal anti-inflammatory drugs and the risk of first-time acute myocardial infarction. Br J Clin Pharmacol. 2002;54:327-332.
7. Solomon DH, Glynn RJ, Levin R, et al. Nonsteroidal anti-inflammatory drug use and acute myocardial infarction. Arch Intern Med. 2002;162: 1099-1104.
8. Watson DJ, Rhodes T, Cai B, et al. Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis. Arch Intern Med. 2002;162:1105-1110.
9. García Rodríguez LA, Varas C, Patrono C. Differential effects of aspirin and non-aspirin nonsteroidal antiinflammatory drugs in the primary prevention of myocardial infarction in postmenopausal women. Epidemiology. 2000;11:382-387.
10. Ray WA, Stein CM, Daugherty JR, et al. COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet. 2002;360:1071-1073.
11. Mamdani M, Rochon P, Juurlink DN, et al. Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly. Intern Med 2003;163:481-486.
12. García Rodríguez LA, Pérez Gutthann S. Use of the UK General Practice Research Database for pharmacoepidemiology. Br J Clin Pharmacol. 1998;45:419-426.
13. Jick H, Jick SS, Derby LE. Validation of information recorded on general practitioner based computerised data resource in the United Kingdom. BMJ. 1991;302:766-768.
14. Gillum RF, Fortmann SP, Prineas RJ, et al. International diagnostic criteria for acute myocardial infarction and acute stroke. Am Heart J. 1984;108:150-158.
15. World Health Organization Regional Office for Europe. Myocardial Infarction Community Registers. Copenhagen: World Health Organization; 1976. Public Health in Europe No. 5.
16. Varas-Lorenzo C, García-Rodriguez LA, Perez-Gutthann S, et al. Hormone replacement therapy and incidence of acute myocardial infarction: a population-based nested case-control study. Circulation. 2000;101:2572-2578.
17. García Rodríguez LA, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet. 1994;343:769-772.
18. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002; 324:71-86.
19. Signorello LB, McLaughlin JK, Lipworth L, et al. Confounding by indication in epidemiologic studies of commonly used analgesics. Am J Ther. 2002;9:199-205.
20. Solomon DH, Karlson EW, Rimm EB, et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation. 2003;107:1303-1307.
21. Wallberg-Jonsson S, Öhman ML, Rantapää-Dahlqvist S. Cardiovascular morbidity mortality in patients with seropositive rheumatoid arthritis in northern Sweden. J Rheumatol. 1997;24:445-451.
22. Gabriel SE, Crowson CS, Kremers HM, et al. Survival in rheumatoid arthritis: a population-based analysis of trends over 40 years. Arthritis Rheum. 2003;48:54-58.
23. Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med. 2001;345: 1809-1817.
24. MacDonald TM, Wei L. Effect of ibuprofen on cardioprotective effect of aspirin. Lancet. 2003;361:573-574.
25. Kurth T, Glynn RJ, Walker AM, et al. Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal antiinflammatory drugs. Circulation. 2003;108:1191-1195.
26. Mc Cornick A, Fleming D, Charlton J. Morbidity Statistics in General Practice: Fourth National Study, 1991-1992. London: HMSO (ONS); 1995. Series MB5 No. 3.